Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710240 · ClinicalTrials.gov registry record · Phase 1
Indocyanine Green for Central Nervous System Tumors
A Phase 1 study of Suspected Central Nervous System Tumors, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 336
- Enrollment target
- 1
- Study location
NCT02710240 is a Phase 1 study of Suspected Central Nervous System Tumors that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 336 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02710240, a Phase 1 study of Suspected Central Nervous System Tumors, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 336 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single center, open-label, two-part study to assess image guided surgery of intramolecular imaging in nervous system tumors. Subjects with a diagnosis of a resectable nervous system tumor who are at risk of recurrence are included. The primary goal is to observe what tissues fluoresce in the OR, and then to identify if that tissue is cancerous/tumor or normal when the histopathology is performed.
Conditions Studied
Interventions
- DRUG Indocyanine Green (ICG)
- RADIATION Intraoperative near-infrared (NIR)
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2015-06-10 |
| Est. Completion | 2020-04-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02710240
The ClinicalTrials.gov registry entry for NCT02710240 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Suspected Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which Indocyanine Green (ICG) is the first listed.
NCT02710240 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02710240 about?
NCT02710240 is a clinical study titled "Indocyanine Green for Central Nervous System Tumors". This study is a single center, open-label, two-part study to assess image guided surgery of intramolecular imaging in nervous system tumors. Subjects with a diagnosis of a resectable nervous system tumor who are at risk of recurrence are included. The primary goal is to observe what tissues fluoresc...
What is the current status of trial NCT02710240?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 336 participants. The study started on 2015-06-10. Estimated completion is 2020-04-02.
What conditions does trial NCT02710240 study?
This clinical trial studies the following conditions: Suspected Central Nervous System Tumors.
What interventions are being tested in trial NCT02710240?
The interventions under investigation include: Indocyanine Green (ICG) (DRUG), Intraoperative near-infrared (NIR) (RADIATION).
Who is sponsoring clinical trial NCT02710240?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710240 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.